X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

IMV

Closed

Imv Inc.

0.0811
0.0000 (0.00%)
Last Update: 26 Jun 2023 16:30:00
Yesterday: 0.0811
Day's Range: 0.0811 - 0.1
Send
When Written:
 
0.5402
IMV Inc. is a clinical-stage biopharmaceutical company that develops immunotherapies for cancer and infectious diseases. The company's lead candidate, DPX-Survivac, is a T-cell activating immunotherapy that targets survivin, a protein that is overexpressed in many cancer types. IMV is also developing DPX-RSV, a vaccine candidate for respiratory syncytial virus (RSV), and DPX-E7, a therapeutic vaccine for human papillomavirus (HPV)-related cancers. IMV's proprietary delivery platform, DPX, uses lipid-based nanoparticles to enhance the immune response to antigens. The company is headquartered in Dartmouth, Nova Scotia, Canada, and has a research facility in Halifax, Nova Scotia. IMV is publicly traded on the NASDAQ and Toronto Stock Exchange under the ticker symbol "IMV."

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X